Large-scale testing (Phase 3)Active Not RecruitingNCT07386938
What this trial is testing
The Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer
Who this might be right for
Locally Advanced Breast CancerMetastatic Breast Cancer
R-Pharm 246